Sun Pharma Buys Organon & Co. for $11.75 Billion in All-Cash Deal
NEW YORK, April 28 —
Sun Pharma is buying Organon & Co. (OGN) for roughly $11.75 billion in cash, a 24% premium to the pre-deal share price.
- Deal value: ~$11.75bn all-cash, representing a 24% premium and pushing OGN to a 52-week high
- Organon trades at just 3.6x forward earnings and generated $6.2bn in TTM revenue
- Watch for: regulatory approval milestones, with closing expected mid-to-late 2026
What Actually Happened
Sun Pharma, India's largest drugmaker, agreed to take out Organon in what would be one of the biggest cross-border pharma deals this year. The $11.75bn price tag covers Organon's equity plus its substantial debt load, which has weighed on the stock since Merck spun it off in 2021. At roughly 1.9x trailing revenue, Sun is not paying a growth multiple. It's paying a leverage-discount multiple.
The strategic logic is straightforward. Sun gets Organon's women's health franchise, its established brands portfolio, and biosimilars pipeline, instantly expanding its geographic reach to 150 countries. Sun is lining up a bridge loan for approximately $12bn to fund the deal. For a company that built its reputation on capital discipline, that is a bold bet.
The Catch
A 24% premium sounds generous until you remember where OGN was trading. At $13.16 before the deal, Organon was a $6.2bn-revenue company valued like a distressed asset. That 3.6x forward P/E tells you the market had real concerns about the debt burden and Nexplanon's patent cliff. Sun is essentially paying a premium on a deeply discounted stock. Long-term OGN holders who bought at the 2021 spin-off price are still underwater, even with the bump.
Then there's execution risk. A $12bn bridge loan for an Indian pharma company acquiring a U.S.-listed target will face scrutiny from multiple regulators. Cross-border pharma M&A has gotten slower, not faster. The mid-to-late 2026 closing timeline leaves months of deal-spread risk on the table.
Bottom Line
If you own OGN, the trade is mostly done. Shares have priced in most of the premium, and what's left is a bet on deal certainty. The spread between the current price and the offer is your compensation for carrying regulatory risk through the end of the year. This is now an arbitrage position, not an equity position.
If you don't own OGN, the more interesting question is whether Sun Pharma can actually digest $11.75bn of acquisition without choking on the financing. The number to watch is the deal spread. If it widens, the market is telling you something about closing risk.
Want a full financial breakdown on Organon? Generate a free Basis Report on OGN here.
Basis Report does not hold positions in securities discussed. This is not investment advice.